Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103905 | 0.86 | CYP3A4 (0.42) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4702765 | 0.82 | CYP3A4 (0.42) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4704578 | 0.82 | ALDH1A1 (0.37) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4705463 | 0.82 | ALDH1A1 (0.37) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4706202 | 0.82 | CYP3A4 (0.39) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4703501 | 0.81 | ALDH1A1 (0.33) | CTSDCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4704282 | 0.78 | CHRM1 (0.44) | ALDH1A1SMN1; SMN2TSHRTACR1HTT | |
| SCHEMBL4705390 | 0.78 | TSHR (0.46) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL3741639 | 0.76 | CTSS (0.48) | CTSLCTSBCTSSALDH1A1SMN1; SMN2 | |
| SCHEMBL4702059 | 0.76 | OPRD1 (0.41) | ALDH1A1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | TP53, TP53BP1, MDM2 | CTSD 3049/4885CTSL 2371/4885CTSB 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.